Clinical Trial and Launch of TLM-003 Myopia Progression Prevention Eye Drops
First written in FY2022. 9 of 12 entries say "Advanced", first in FY2023-Q2. Latest entry: 2026-06-25.
No other company in this theme has enough history to compare yet.
- 2026-06-25RestatedManagement Planning
「Phase 2 ongoing (Japan and overseas)」
The company reconfirmed that domestic and overseas Phase II clinical trials for TLM-003 are ongoing. - FY2026AdvancedAnnual report
「Rohto Pharmaceutical completed the Phase 1 clinical trial and confirmed safety, and the Phase 2 clinical trial is now ongoing. Laboratoires Théa, which signed an exclusive license agreement in December 2022, has also initiated an overseas Phase 2 clinical trial, advancing clinical development in Japan and overseas.」
TLM-003 has progressed from a domestic Phase 1 to a Phase 2 trial, and Laboratoires Théa, the overseas licensee, has also initiated a Phase 2 trial. - FY2026-H1AdvancedAnnual report
「In the myopia field, the Phase 2 clinical trial in Japan of TLM-003, an eye drop covered by the long-term development agreement with Rohto Pharmaceutical Co., Ltd., is progressing smoothly. Preparations for an overseas Phase 2 trial are also steadily advancing.」
The domestic Phase 2 clinical trial of TLM-003 is ongoing, and preparations for an overseas Phase 2 trial have also advanced. - FY2024AdvancedAnnual report
「TLM-003, a drug to suppress myopia progression, is covered by a long-term development agreement with Rohto Pharmaceutical Co., Ltd. Rohto Pharmaceutical began a Phase 1 clinical trial in Japan in November 2023.」
Rohto Pharmaceutical began a domestic Phase 1 clinical trial of TLM-003 in November 2023. - FY2024-Q3AdvancedAnnual report
「In addition, a domestic clinical trial (Phase 1) of TLM-003 has been initiated by our partner, Rohto Pharmaceutical Co., Ltd.」
Rohto Pharmaceutical has initiated a domestic Phase 1 clinical trial of TLM-003. - FY2023RestatedAnnual report
「We have entered into a long-term development agreement with Rohto Pharmaceutical Co., Ltd. and plan to conduct clinical trials and launch the product as an eye drop for preventing myopia.」
The clinical development and commercialization plan for TLM-003 is ongoing. The exclusive license agreement with Laboratoires Théa covering the United States and Europe had already been signed by the previous quarter, and this filing reconfirms the commercialization plan. - FY2023-Q3AdvancedAnnual report
「For TLM-003, we achieved a milestone under the joint research and development agreement and entered into a new license agreement covering the United States and Europe.」
For TLM-003, the company achieved a milestone under the joint research and development agreement and entered into a new exclusive license agreement covering the United States and Europe. - FY2023-Q2AdvancedAnnual report
「We have achieved a milestone under the joint research and development agreement for TLM-003, an eye drop that suppresses myopia progression.」
The company states that it has achieved a milestone under the joint research and development agreement advancing development of TLM-003. - FY2022First statedAnnual report
「TLM-003 is a new type of eye drop that prevents myopia progression with administration once or twice daily. Its efficacy in suppressing myopia progression has already been demonstrated in animal studies using mice. We have entered into a long-term development agreement with Rohto Pharmaceutical Co., Ltd. and plan to conduct clinical trials and launch it as an eye drop for preventing myopia.」
A long-term development plan progressing from animal studies to clinical trials and commercialization.